Rituximab (Arm B) ( DrugBank: Rituximab )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
43	Microscopic polyangiitis	1
44	Wegener granulomatosis	1

43. Microscopic polyangiitis

---

Clinical trials : 88 /  Drugs : 81 - (DrugBank : 21) / Drug target genes : 15 - Drug target pathways : 90

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01731561 (ClinicalTrials.gov)	November 16, 2012	12/10/2012	Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis	MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II	Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Renal Limited Forms	Drug: Rituximab (Arm B);Drug: Rituximab (Arm A)	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	All	166	Phase 3	France

44. Wegener granulomatosis

---

Clinical trials : 98 /  Drugs : 108 - (DrugBank : 28) / Drug target genes : 22 - Drug target pathways : 81

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01731561 (ClinicalTrials.gov)	November 16, 2012	12/10/2012	Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis	MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II	Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Renal Limited Forms	Drug: Rituximab (Arm B);Drug: Rituximab (Arm A)	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	All	166	Phase 3	France